Pfizer Reports Phase 3 Data for Lisocabtagene maraleucel in Migraine

Pfizer today announced Phase 3 results for lisocabtagene maraleucel in patients with migraine. The study demonstrated that lisocabtagene maraleucel reduces exacerbation rates compared to standard of care or placebo. These results provide important insights into the treatment of migraine and support the continued development of lisocabtagene maraleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.